BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abgral R, Leboulleux S, Déandreis D, Aupérin A, Lumbroso J, Dromain C, Duvillard P, Elias D, de Baere T, Guigay J, Ducreux M, Schlumberger M, Baudin E. Performance of (18)fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki67 (≥10%) well-differentiated endocrine carcinoma staging. J Clin Endocrinol Metab 2011;96:665-71. [PMID: 21193541 DOI: 10.1210/jc.2010-2022] [Cited by in Crossref: 67] [Cited by in F6Publishing: 51] [Article Influence: 5.6] [Reference Citation Analysis]
Number Citing Articles
1 Naik M, Al-Nahhas A, Khan SR. Treatment of Neuroendocrine Neoplasms with Radiolabeled Peptides-Where Are We Now. Cancers (Basel) 2022;14:761. [PMID: 35159027 DOI: 10.3390/cancers14030761] [Reference Citation Analysis]
2 Cazzato RL, Hubelé F, De Marini P, Ouvrard E, Salvadori J, Addeo P, Garnon J, Kurtz JE, Greget M, Mertz L, Goichot B, Gangi A, Imperiale A. Liver-Directed Therapy for Neuroendocrine Metastases: From Interventional Radiology to Nuclear Medicine Procedures. Cancers (Basel) 2021;13:6368. [PMID: 34944988 DOI: 10.3390/cancers13246368] [Reference Citation Analysis]
3 Papadakis GZ, Karantanas AH, Marias K, Millo C. Current status and future prospects of PET-imaging applications in patients with gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs). Eur J Radiol 2021;143:109932. [PMID: 34482177 DOI: 10.1016/j.ejrad.2021.109932] [Reference Citation Analysis]
4 Abgral R, Bourhis D, Salaun PY. Clinical perspectives for the use of total body PET/CT. Eur J Nucl Med Mol Imaging 2021;48:1712-8. [PMID: 33742236 DOI: 10.1007/s00259-021-05293-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Thuillier P, Liberini V, Rampado O, Gallio E, De Santi B, Ceci F, Metovic J, Papotti M, Volante M, Molinari F, Deandreis D. Diagnostic Value of Conventional PET Parameters and Radiomic Features Extracted from 18F-FDG-PET/CT for Histologic Subtype Classification and Characterization of Lung Neuroendocrine Neoplasms. Biomedicines 2021;9:281. [PMID: 33801987 DOI: 10.3390/biomedicines9030281] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Prinzi N, Rossi RE, Proto C, Leuzzi G, Raimondi A, Torchio M, Milione M, Corti F, Colombo E, Prisciandaro M, Cascella T, Spreafico C, Beninato T, Coppa J, Lo Russo G, Di Bartolomeo M, de Braud F, Pusceddu S. Recent Advances in the Management of Typical and Atypical Lung Carcinoids. Clin Lung Cancer 2021;22:161-9. [PMID: 33618994 DOI: 10.1016/j.cllc.2020.12.004] [Reference Citation Analysis]
7 Li D, Rock A, Kessler J, Ballena R, Hyder S, Mo C, Chang S, Singh G. Understanding the Management and Treatment of Well-Differentiated Pancreatic Neuroendocrine Tumors: A Clinician's Guide to a Complex Illness. JCO Oncol Pract 2020;16:720-8. [PMID: 33085933 DOI: 10.1200/JCOOP.20.00010] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Perrier M, Hentic O, Walter T, Cao CD, Cadiot G, de Mestier L; Groupe d’étude des Tumeurs Endocrines (GTE). Clinical usefulness of FDG-PET for management of well-differentiated digestive neuroendocrine tumors. Dig Liver Dis 2020;52:1521-4. [PMID: 32962966 DOI: 10.1016/j.dld.2020.09.001] [Reference Citation Analysis]
9 Souche R, Hobeika C, Hain E, Gaujoux S. Surgical Management of Neuroendocrine Tumours of the Pancreas. J Clin Med. 2020;9. [PMID: 32947997 DOI: 10.3390/jcm9092993] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
10 Peri M, Fazio N. Clinical Evaluation of Everolimus in the Treatment of Neuroendocrine Tumors of the Lung: Patient Selection and Special Considerations. A Systematic and Critical Review of the Literature. Lung Cancer (Auckl) 2020;11:41-52. [PMID: 32753993 DOI: 10.2147/LCTT.S249928] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Jeune F, Taibi A, Gaujoux S. Update on the Surgical Treatment of Pancreatic Neuroendocrine Tumors. Scand J Surg. 2020;109:42-52. [PMID: 31975647 DOI: 10.1177/1457496919900417] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
12 Hain E, Sindayigaya R, Fawaz J, Gharios J, Bouteloup G, Soyer P, Bertherat J, Prat F, Terris B, Coriat R, Gaujoux S. Surgical management of pancreatic neuroendocrine tumors: an introduction. Expert Rev Anticancer Ther 2019;19:1089-100. [PMID: 31825691 DOI: 10.1080/14737140.2019.1703677] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
13 Duan H, Baratto L, Iagaru A. The Role of PET/CT in the Imaging of Pancreatic Neoplasms. Semin Ultrasound CT MR 2019;40:500-8. [PMID: 31806148 DOI: 10.1053/j.sult.2019.04.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 de Mestier L, Armani M, Cros J, Hentic O, Rebours V, Cadiot G, Sauvanet A, Couvelard A, Lebtahi R, Ruszniewski P. Lesion-by-lesion correlation between uptake at FDG PET and the Ki67 proliferation index in resected pancreatic neuroendocrine tumors. Digestive and Liver Disease 2019;51:1720-4. [DOI: 10.1016/j.dld.2019.06.022] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
15 Treglia G, Goichot B, Giovanella L, Hindié E, Jha A, Pacak K, Taïeb D, Walter T, Imperiale A. Prognostic and predictive value of nuclear imaging in endocrine oncology. Endocrine 2020;67:9-19. [PMID: 31734779 DOI: 10.1007/s12020-019-02131-4] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Berner AM, Pipinikas C, Ryan A, Dibra H, Moghul I, Webster A, Luong TV, Thirlwell C. Diagnostic Approaches to Neuroendocrine Neoplasms of Unknown Primary Site. Neuroendocrinology 2020;110:563-73. [PMID: 31658461 DOI: 10.1159/000504370] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
17 Lamarca A, Clouston H, Barriuso J, McNamara MG, Frizziero M, Mansoor W, Hubner RA, Manoharan P, O'Dwyer S, Valle JW. Follow-Up Recommendations after Curative Resection of Well-Differentiated Neuroendocrine Tumours: Review of Current Evidence and Clinical Practice. J Clin Med 2019;8:E1630. [PMID: 31590343 DOI: 10.3390/jcm8101630] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Kanduluru AK, Srinivasarao M, Wayua C, Low PS. Evaluation of a Neurokinin-1 Receptor-Targeted Technetium-99m Conjugate for Neuroendocrine Cancer Imaging. Mol Imaging Biol 2020;22:377-83. [PMID: 31292915 DOI: 10.1007/s11307-019-01391-w] [Reference Citation Analysis]
19 Gharios J, Hain E, Dohan A, Prat F, Terris B, Bertherat J, Coriat R, Dousset B, Gaujoux S. Pre- and intraoperative diagnostic requirements, benefits and risks of minimally invasive and robotic surgery for neuroendocrine tumors of the pancreas. Best Pract Res Clin Endocrinol Metab. 2019;33:101294. [PMID: 31351817 DOI: 10.1016/j.beem.2019.101294] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
20 Jiang Y, Hou G, Cheng W. The utility of 18F-FDG and 68Ga-DOTA-Peptide PET/CT in the evaluation of primary pulmonary carcinoid: A systematic review and meta-analysis. Medicine (Baltimore) 2019;98:e14769. [PMID: 30855482 DOI: 10.1097/MD.0000000000014769] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 4.3] [Reference Citation Analysis]
21 Bergeret S, Charbit J, Ansquer C, Bera G, Chanson P, Lussey-Lepoutre C. Novel PET tracers: added value for endocrine disorders. Endocrine 2019;64:14-30. [PMID: 30875057 DOI: 10.1007/s12020-019-01895-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
22 Gornes H, Vaysse C, Deslandres M, Perallon R, Chantalat E, Rimailho J. Discovery of a neuroendocrine tumor of the caecum by mammary metastasis using 18F-DOPA-PET. J Obstet Gynaecol Res 2018;44:2195-8. [PMID: 30117240 DOI: 10.1111/jog.13776] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
23 Liu S, Feng Z, Wen H, Jiang Z, Pan H, Deng Y, Zhang L, Ju X, Chen X, Wu X. 18F-FDG PET/CT can predict chemosensitivity and proliferation of epithelial ovarian cancer via SUVmax value. Jpn J Radiol 2018;36:544-50. [PMID: 29943313 DOI: 10.1007/s11604-018-0755-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
24 Zhang P, Yu J, Li J, Shen L, Li N, Zhu H, Zhai S, Zhang Y, Yang Z, Lu M. Clinical and Prognostic Value of PET/CT Imaging with Combination of 68Ga-DOTATATE and 18F-FDG in Gastroenteropancreatic Neuroendocrine Neoplasms. Contrast Media Mol Imaging 2018;2018:2340389. [PMID: 29681780 DOI: 10.1155/2018/2340389] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
25 Kornaczewski Jackson ER, Pointon OP, Bohmer R, Burgess JR. Utility of FDG-PET Imaging for Risk Stratification of Pancreatic Neuroendocrine Tumors in MEN1. J Clin Endocrinol Metab 2017;102:1926-33. [PMID: 28323985 DOI: 10.1210/jc.2016-3865] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
26 Hadoux J, Terroir M, Leboulleux S, Deschamps F, Al Ghuzlan A, Hescot S, Tselikas L, Borget I, Caramella C, Déandréis D, Goere D, De Baere T, Schlumberger M, Baudin E. Interferon-alpha Treatment for Disease Control in Metastatic Pheochromocytoma/Paraganglioma Patients. HORM CANC 2017;8:330-7. [DOI: 10.1007/s12672-017-0303-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
27 Abdulrezzak U, Kurt YK, Kula M, Tutus A. Combined imaging with 68Ga-DOTA-TATE and 18F-FDG PET/CT on the basis of volumetric parameters in neuroendocrine tumors. Nucl Med Commun 2016;37:874-81. [PMID: 27096719 DOI: 10.1097/MNM.0000000000000522] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
28 Dromain C, Déandréis D, Scoazec JY, Goere D, Ducreux M, Baudin E, Tselikas L. Imaging of neuroendocrine tumors of the pancreas. Diagn Interv Imaging 2016;97:1241-57. [PMID: 27876341 DOI: 10.1016/j.diii.2016.07.012] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 7.7] [Reference Citation Analysis]
29 Deroose CM, Hindié E, Kebebew E, Goichot B, Pacak K, Taïeb D, Imperiale A. Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions. J Nucl Med 2016;57:1949-56. [PMID: 27811124 DOI: 10.2967/jnumed.116.179234] [Cited by in Crossref: 75] [Cited by in F6Publishing: 64] [Article Influence: 12.5] [Reference Citation Analysis]
30 de Mestier L, Deguelte-lardière S, Brixi H, Kianmanesh R, Cadiot G. Tumeurs neuroendocrines digestives. La Revue de Médecine Interne 2016;37:551-60. [DOI: 10.1016/j.revmed.2016.01.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
31 Pusceddu S, Lo Russo G, Macerelli M, Proto C, Vitali M, Signorelli D, Ganzinelli M, Scanagatta P, Duranti L, Trama A, Buzzoni R, Pelosi G, Pastorino U, de Braud F, Garassino MC. Diagnosis and management of typical and atypical lung carcinoids. Crit Rev Oncol Hematol 2016;100:167-76. [PMID: 26917456 DOI: 10.1016/j.critrevonc.2016.02.009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
32 Morgat C, Vélayoudom-Céphise FL, Schwartz P, Guyot M, Gaye D, Vimont D, Schulz J, Mazère J, Nunes ML, Smith D, Hindié E, Fernandez P, Tabarin A. Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1. Eur J Nucl Med Mol Imaging 2016;43:1258-66. [PMID: 26819103 DOI: 10.1007/s00259-016-3319-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
33 Lapa C, Werner RA, Herrmann K. Visualization of tumor heterogeneity in neuroendocrine tumors by positron emission tomography. Endocrine 2016;51:556-7. [PMID: 26084261 DOI: 10.1007/s12020-015-0661-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
34 Caplin ME, Baudin E, Ferolla P, Filosso P, Garcia-Yuste M, Lim E, Oberg K, Pelosi G, Perren A, Rossi RE, Travis WD;  ENETS consensus conference participants. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol. 2015;26:1604-1620. [PMID: 25646366 DOI: 10.1093/annonc/mdv041] [Cited by in Crossref: 281] [Cited by in F6Publishing: 265] [Article Influence: 40.1] [Reference Citation Analysis]
35 Grimaldi F, Fazio N, Attanasio R, Frasoldati A, Papini E, Angelini F, Baldelli R, Berretti D, Bianchetti S, Bizzarri G, Caputo M, Castello R, Cremonini N, Crescenzi A, Davì MV, D'Elia AV, Faggiano A, Pizzolitto S, Versari A, Zini M, Rindi G, Oberg K. Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms. J Endocrinol Invest 2014;37:875-909. [PMID: 25038902 DOI: 10.1007/s40618-014-0119-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
36 de Mestier L, Dromain C, d'Assignies G, Scoazec J, Lassau N, Lebtahi R, Brixi H, Mitry E, Guimbaud R, Courbon F, d'Herbomez M, Cadiot G. Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art. Endocrine-Related Cancer 2014;21:R105-20. [DOI: 10.1530/erc-13-0365] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
37 Hadoux J, Favier J, Scoazec JY, Leboulleux S, Al Ghuzlan A, Caramella C, Déandreis D, Borget I, Loriot C, Chougnet C, Letouzé E, Young J, Amar L, Bertherat J, Libé R, Dumont F, Deschamps F, Schlumberger M, Gimenez-Roqueplo AP, Baudin E. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. Int J Cancer 2014;135:2711-20. [PMID: 24752622 DOI: 10.1002/ijc.28913] [Cited by in Crossref: 91] [Cited by in F6Publishing: 92] [Article Influence: 11.4] [Reference Citation Analysis]
38 Beylergil V, Carrasquillo JA. Molecular imaging and therapy of merkel cell carcinoma. Cancers (Basel) 2014;6:1020-30. [PMID: 24784954 DOI: 10.3390/cancers6021020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
39 de Herder WW. GEP-NETS update: functional localisation and scintigraphy in neuroendocrine tumours of the gastrointestinal tract and pancreas (GEP-NETs). Eur J Endocrinol 2014;170:R173-83. [PMID: 24723670 DOI: 10.1530/EJE-14-0077] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
40 Gaujoux S, Sauvanet A, Partelli S, Falconi M, Ruszniewski P. Comment on “Predicting aggressive behavior in nonfunctioning pancreatic neuroendocrine”. Surgery 2014;155:582-4. [DOI: 10.1016/j.surg.2013.11.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
41 van Essen M, Sundin A, Krenning EP, Kwekkeboom DJ. Neuroendocrine tumours: the role of imaging for diagnosis and therapy. Nat Rev Endocrinol. 2014;10:102-114. [PMID: 24322649 DOI: 10.1038/nrendo.2013.246] [Cited by in Crossref: 98] [Cited by in F6Publishing: 85] [Article Influence: 10.9] [Reference Citation Analysis]
42 Panagiotidis E, Bomanji J. Role of 18F-fluorodeoxyglucose PET in the study of neuroendocrine tumors. PET Clin 2014;9:43-55. [PMID: 25029933 DOI: 10.1016/j.cpet.2013.08.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
43 Vélayoudom-Céphise FL, Duvillard P, Foucan L, Hadoux J, Chougnet CN, Leboulleux S, Malka D, Guigay J, Goere D, Debaere T. Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endocr Relat Cancer. 2013;20:649-657. [PMID: 23845449 DOI: 10.1530/erc-13-0027] [Cited by in Crossref: 187] [Cited by in F6Publishing: 181] [Article Influence: 20.8] [Reference Citation Analysis]
44 García-Carbonero R, Vilardell F, Jiménez-Fonseca P, González-Campora R, González E, Cuatrecasas M, Capdevila J, Aranda I, Barriuso J, Matías-Guiu X; Spanish Society of Pathology., Spanish Society of Medical Oncology. Guidelines for biomarker testing in gastroenteropancreatic neuroendocrine neoplasms: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol 2014;16:243-56. [PMID: 23749327 DOI: 10.1007/s12094-013-1062-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
45 Chougnet CN, Leboulleux S, Caramella C, Lumbroso J, Borget I, Déandreis D, Duvillard P, Elias D, de Baere T, Vélayoudom-céphise F, Guigay J, Ducreux M, Schlumberger M, Baudin E. Frequency and characterization of gastro–entero–pancreatic neuroendocrine tumor patients with high-grade of uptake at somatostatin receptor scintigraphy. Endocrine-Related Cancer 2013;20:229-39. [DOI: 10.1530/erc-12-0169] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
46 Balogova S, Talbot JN, Nataf V, Michaud L, Huchet V, Kerrou K, Montravers F. 18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type. Eur J Nucl Med Mol Imaging 2013;40:943-66. [PMID: 23417499 DOI: 10.1007/s00259-013-2342-x] [Cited by in Crossref: 76] [Cited by in F6Publishing: 56] [Article Influence: 8.4] [Reference Citation Analysis]
47 Gaujoux S, Sauvanet A, Belghiti J. Place of surgical resection in the treatment strategy of gastrointestinal neuroendocrine tumors. Target Oncol 2012;7:153-9. [PMID: 22923166 DOI: 10.1007/s11523-012-0230-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
48 Kuyumcu S, Adalet I, Sanli Y, Turkmen C, Ozkan ZG, Yilmazbayhan D. Somatostatin receptor scintigraphy with 111In-octreotide in pulmonary carcinoid tumours correlated with pathological and 18FDG PET/CT findings. Ann Nucl Med 2012;26:689-97. [PMID: 22802007 DOI: 10.1007/s12149-012-0628-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
49 Haug AR, Bartenstein P. [Gastroenteropancreatic neuroendocrine tumors: diagnosis and therapy in nuclear medicine]. Internist (Berl) 2012;53:161-6. [PMID: 22231696 DOI: 10.1007/s00108-011-2918-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
50 Rust E, Hubele F, Marzano E, Goichot B, Pessaux P, Kurtz JE, Imperiale A. Nuclear medicine imaging of gastro-entero-pancreatic neuroendocrine tumors. The key role of cellular differentiation and tumor grade: from theory to clinical practice. Cancer Imaging 2012;12:173-84. [PMID: 22743056 DOI: 10.1102/1470-7330.2012.0026] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
51 Deandreis D, Leboulleux S, Caramella C, Schlumberger M, Baudin E. FDG PET in the Management of Patients with Adrenal Masses and Adrenocortical Carcinoma. HORM CANC 2011;2:354-62. [DOI: 10.1007/s12672-011-0091-5] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]